Pain

The new requirements follow a May Advisory Committee meeting that went over the latest long-term data on opioid risks.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

Angel Goenawan, MD, shared findings from a meta-analysis of surgical and nonsurgical clinical trials.

The Best Practice Advice is aimed at detailing benefits and harms of cannabis or cannabinoids in the management of chronic noncancer pain.

The first quarter of 2025 saw approvals in diabetes, depression, kidney disease, and pain, among others. Read more about high-impact approvals of Q1 now.

Mukkamala discussed other priorities the AMA’s Substance Use and Pain Care Task Force is tackling with OUD.

Our top 5 headlines featured an oral drug delivering 16% weight loss, notable blood pressure reductions from a hypertension treatment, and 3 key FDA decisions.

Mukkamala also discussed the importance of expanding non-opioid pain relief options.

A study found a strong link between headache disorders and suicide risk, including tension-type headaches.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

The FDA approval of suzetrigine, a non-opioid pain signal inhibitor, may help address the needs of patients with moderate-to-severe acute pain.

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

Crisugabalin at 40 mg/d or 80 mg/d significantly reduced daily pain in adults with postherpetic neuralgia, a phase 3 study found.

FDA issued a CRL the abbreviated new drug application of ketamine, which had sought to enhance accessibility to the limited drug supply.

The FDA identified high concentration of lidocaine across marketed, over-the-counter topical products from 6 different companies.

The 2016 CDC guidelines led to significant decreases in opioid prescriptions and an increase in pain-related healthcare utilization for people with sickle cell disease.

Lio shares 3 aspects of pain management that dermatologists can consider to improve the experience of procedures for patients.

Melanie Lewis, RN, writes about how listening to patients, conducting nerve conduction studies, and referring to specialists are key actions to provide effective care in patients dealing with chronic pain.

VX-548 demonstrated a more rapid onset to meaningful pain relief post-surgery compared with placebo.

On January 23, 2024, Heron Therapeutics announced the FDA had approved its sNDA for bupivacaine and meloxicam extended-release solution to expand the indication to include soft tissue and orthopedic surgical procedures, including procedures in which direct exposure to articular cartilage is avoided.

The FDA has extended the shelf-life of 4 mg naloxone hydrochloride nasal spray (Narcan) for nonprescription over-the-counter use from 3 years to 4 years.

At the 48-hour mark, the mean difference between high-dose VX-548 and placebo was 37.8 in the abdominoplasty group and 36.8 in the bunionectomy group, thus demonstrating the drug's pain relief potential.

RiVive is the second nonprescription naloxone product approved by the FDA, signaling a proactive effort to increase accessibility and consumer availability of life-saving medication.

Most (73%) patients surveyed expressed they sought to completely stop or never start using opioids for their chronic pain.